The counter had a total traded volume of 10:30AM shares so far with a turnover of Rs 4.61 crore on BSE. The stock traded at a price-to-earnings multiple of 13.9 and a price-to-book ratio of 2.36.
A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
Promoters held 51.83 per cent stake in the company as of 31-Dec-2021, while foreign investors and domestic institutional investors ownership stood at 22.74 per cent and 15.11 per cent, respectively.
The company reported consolidated net sales of Rs 6067.21 crore for the quarter ended 31-Dec-2021, up 0.48 per cent from the previous quarter’s Rs 6038.5 crore and up 6.63 per cent from the year-ago quarter’s Rs 6498.31 crore.
Its profit for the latest quarter stood at Rs 604.73 crore, down 79.48 per cent from the same quarter a year ago.